REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is

REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced

Entered into a definitive merger agreement with Advaxis Inc. – transaction expected to close by end of Q1 2023, subject to approval by Ayala’s shareholders and the satisfaction of customary closing conditions Interim positive data from Part A of the RINGSIDE study presented at ESMO demonstrated

Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62 .5% and 37 .5 %

Event will feature a review of data from part A of the Phase 2/3 RINGSIDE trial of AL102 KOL s and m anagement to p resent on Thursday, October 6 th @ 8 AM ET REHOVOT, Israel and WILMINGTON, Del., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc.

REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers today announced

- Updated interim results from Part A of RINGSIDE show first confirmed partial response (PR) achieved at week 16 and 3 additional unconfirmed PRs over the follow-up period - - Consistent early tumor shrinkage with measures deepening over time - - AL102 was well tolerated at all doses evaluated - -

Oral presentation will feature results from Part A of the Phase 2/3 RINGSIDE clinical study REHOVOT, Israel and WILMINGTON, Del., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule

Interim data from Part A of the RINGSIDE study demonstrated substantial initial anti-tumor activity for AL102 as a single agent and supports continued development More advanced and comprehensive data set from RINGSIDE to be presented at ESMO REHOVOT, Israel and WILMINGTON, Del., Aug.

- Tumor shrink ing observed in substantially all patients who were evaluable at 16 weeks - - Favorable safety results observed : AL102 was well tolerated - - Additional data to be submitted for presen t ation at a medical conference in 2H 2022 - REHOVOT, Israel & WILMINGTON, Del., July 05, 2022